EBS · —

Santhera Pharmaceuticals Holding AG (SANN.SW) Stock

$15.88 +2.45% EBS: SANN.SW —

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy.

Valuation

MetricValue
Price$15.88
Market Cap—
P/E Ratio—
P/B Ratio—
P/S Ratio—
EPS (TTM)—
52-Week High$18.84
52-Week Low$9.38
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin—
Operating Margin—
Net Margin—
Debt/Equity—
Current Ratio—

Latest News

Farizon Hits 600,000 Production Milestone, Celebrates 10th Anniversary with Homtruck Rollout PR Newswire · Aug 13, 2026 X Square Robot Demonstrates Embodied AI in Real-World Logistics Operations PR Newswire · Aug 13, 2026 Allient (ALNT) Q2 2026 Earnings Call Transcript Motley Fool · Aug 13, 2026 McEwen (MUX) Q2 2026 Earnings Call Transcript Motley Fool · Aug 13, 2026 The Hidden Red Flag in Wall Street’s Price Targets Barrons.com · Aug 13, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y22.83%
Return 3Y96.35%
Return 5Y-20.88%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADXN.SWAddex Therapeutics Ltd $0.04 +0.00% — — 0.00%
ASCN.SWAscom Holding AG $5.52 -3.50% — — 0.00%
CLTN.SWCOLTENE Holding AG $48.35 -4.07% — — 0.00%
DOCM.SWDocMorris AG $9.46 -0.42% — — 0.00%
EVE.SWEvoNext Holdings SA $2.08 -2.35% -23.11 $15.00M 0.00%

About Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding AG is led by CEO Orlando Oliveira, employs 78 people, headquartered in Pratteln, CH, publicly traded since 2006.

over the past 52 weeks the stock has ranged between $9.38 and $18.84, and currently trades 15.7% below its 52-week high.

Official website: www.santhera.com

Related — Stocks

BNY — $152.52 -2.54% CIEN — $412.39 +2.14% CBRS — $188.61 -5.28% HEI.A AIRCRAFT ENGINES & ENGINE PARTS $216.35 +0.00% LEN.B GENERAL BLDG CONTRACTORS - RESIDENTIAL BLDGS $80.32 +0.00% WSO.B WHOLESALE-HARDWARE & PLUMBING & HEATING EQUIPMENT & SUPPLIES $453.37 +0.00% MKC.V MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS $51.78 +0.00% MOG.B MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT $322.00 +0.00% MOG.A MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT $307.91 +0.00% UHAL.B SERVICES-AUTO RENTAL & LEASING (NO DRIVERS) $45.71 +0.00% TAP.A MALT BEVERAGES $47.89 +0.00% VSXY — $88.68 +0.50%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides